02257 SIRNAOMICS-B
- 8.130
- -0.170-2.05%
SIRNAOMICS-B News
Statistics on changes in the share of Zhitong Hong Kong Stock Connect | May 22
Statistics on changes in the share of Zhitong Hong Kong Stock Connect | May 21, 2024
Sirnaomics' Strategy Chief Steps Down
Sirnaomics (HKG:2257) said its chief strategy officer Xiaochang Dai resigned, effective May 17, due to personal reasons, according to a Friday filing on the Hong Kong bourse. The company's shares were
Statistics on changes in the share of Zhitong Hong Kong Stock Connect | May 20
According to data disclosed on May 17, 2024, Beijing Capital Finance International (01468.HK), Allian International Education Leasing (01563.HK), and COSMOPOL INT'L (00120.HK) Hong Kong Stock Connect held the largest share increases of 4.86%, 1.32%, and 1.20%, respectively; Shengnuo Pharmaceutical-B (02257.HK), Zhiyun Health (09955.HK), and Hang Seng China Enterprise (02828.HK) saw the biggest decrease in Hong Kong Stock Connect shares, which decreased by 1.46% and -1.46%, respectively -0.94% , -0.67%
Shengnuo Pharmaceutical-B (02257): Dai Xiaochang resigns as Chief Strategy Officer
Shengnuo Pharmaceutical-B (02257) issued an announcement. Dai Xiaochang has resigned as the Group's Chief Strategy Officer due to personal reasons, since 2...
Express News | CITIC Construction Investment: The national biotechnology and biomanfacture action plan is expected to be introduced in the near future, and the subsequent implementation of the policy is worth looking forward to
Shengnuo Pharmaceutical-B (02257): Wang Yongxiang was appointed as Executive Director
Shengnuo Pharmaceutical-B (02257) announced that Dr. Wang Yongxiang was appointed as an executive director from May 1, 2024...
Hong Kong pharmaceutical stocks rose, and Shengnuo Pharmaceutical-B rose more than 16%
Hong Kong pharmaceutical stocks rose; Shengnuo Pharmaceutical-B rose more than 16%, Zaiding Pharmaceuticals rose nearly 10%, and BeiGene Shenzhou rose more than 6%.
Agency: The synthetic biology sector showed a high increase in Q1 performance, and policy expectations accelerated valuation repair
Currently, the core competitiveness of biological manufacturing companies lies in product development and implementation capabilities. They are optimistic about targets with successful cases, leading positions, high-quality product reserves, and a boom in downstream demand.
Baili Tianheng and Shenzhou Cell turned losses into profits! Many biomedical companies on the Science and Technology Innovation Board ushered in a “good start” in Q1
In the first quarter of 2024, many parts of the country successively issued relevant policies to support the high-quality development of the biomedical industry or innovative pharmaceutical devices to continuously optimize the biomedical innovation environment.
聖諾醫藥-B：2023年度報告
Zhitong Hong Kong Stock Short Position Statement Statistics|April 26
Zhitong Hong Kong Stock Short Position Statement | April 26
Statistics on changes in the share of Zhitong Hong Kong Stock Connect | April 26
According to data disclosed on April 25, 2024, Shengnuo Pharmaceutical-B (02257.HK), Tiger Pharmaceuticals (03347.HK), and Peer Hunting (06100.HK) Hong Kong Stock Connect held the largest share value added, increasing 0.58%, 0.47%, and 0.39% respectively; China Alcoa International (02068.HK), Luoyang Yiye (03993.HK), and Country Garden Services (06098.HK) had the largest share losses, decreasing -0.0.75%, -0.3%, respectively -0.57%.
Sirnaomics Receives US FDA Guidance on Trials for Squamous Cell Carcinoma Treatment
Sirnaomics (HKG:2257) received guidance from the US Food and Drug Administration for the drugmaker's phase 2/3 and phase 3 clinical studies of STP705 for treating squamous cell carcinoma in situ. The
Cash flow is about to run out, and Shengnuo Pharmaceutical-B (02257) is surging only to “trick people”?
The stock price dropped 90% within a year, and the majority shareholders were forced to close their positions last month. At this juncture, the stock price suddenly surged more than 20%, which is probably not a good thing for Shengnuo Pharmaceutical-B (02257). On April 17, Shengnuo Pharmaceutical's stock price opened higher in early trading, reaching a maximum increase of 37.87%. According to the news, Shengnuo Pharmaceutical announced on the same day that the company has obtained a written response from the US FDA's Class C meeting on the requirements of its core product STP705. The company has initiated the required preclinical studies in accordance with FDA guidance recommendations. According to the Zhitong Finance App, the purpose of the Class C conference mentioned above was to obtain F
Hong Kong Stock Afternoon Review | Hang Seng Index and Technology Index fell slightly; chip stocks rose more than 5% in Fudan, Shanghai
Heavy infrastructure stocks generally rose; China Zhongzhi and China Railway rose about 3%; gaming stocks continued to decline, and Galaxy Entertainment fell more than 5%.
Shengnuo Pharmaceutical-B (02257): Further development of STP705 for sirnaomics to treat squamous cell carcinoma in situ obtained specific guidance from the FDA
Shengnuo Pharmaceutical-B (02257) issued an announcement. The company has obtained information from the US Food and Drug Administration (FDA)...
Changes in Hong Kong stocks | Shengnuo Pharmaceutical-B (02257.HK) fell more than 11% in the afternoon to a record low, the company's cash flow is in a hurry, and no products have been commercialized
Shengnuo Pharmaceutical-B (02257.HK) fell more than 11% in the afternoon to a new low. Recently, the stock price has continued to decline, with the biggest drop of more than 93% from its all-time high. As of press release, it fell 11.07% to HK$6.43, with a turnover of HK$16.9093 million.
Changes in Hong Kong stocks | Shengnuo Pharmaceutical-B (02257.HK) fell nearly 5%, directors' salary increases raised questions in the market, and the company's cash flow was urgent
Shengnuo Pharmaceutical-B (02257.HK) fell nearly 5%. As of press release, it was down 4.79% to HK$7.55, with a turnover of HK$4.724,200.
Express News | CEO of Shengnuo Pharmaceuticals: There is no risk that the shares held will be forcibly sold
Sirnaomics Announces 2023 Full Year Results
Focus on integrating resources into leading development projects to promote clinical research on the core products STP705, STP707 and STP122G Hong Kong, Germany City, Maryland, and Suzhou, China, March 28, 2024/PRNewswire/ -- Sirnaomics Ltd. (the “Company”, together with its subsidiaries, collectively referred to as “SirnaOmics” or the “Group”; stock code: 2257), an industry-leading biopharmaceutical company focused on developing and creating RNAi drugs, announced the year ended December 31, 2023 Review of (“this year”)
Analysis
Price Target
No Data
